KETOCONAZOLE
This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.
Global evidence snapshot
The resolved identity has matching regulatory evidence in 8 of 13 indexed market datasets: 8 country records and 0 EU Annex records. Every result and evidence gap is listed below.
Resolved substance identity
Ketoconazole is the heterocyclic compound that conforms to the formula
Inventory restriction note: II/1528
8 matched or reported names
Regulatory evidence in all 13 markets
Open each matched record for its scope, concentration, conditions, warnings and official source version.
Swipe or scroll horizontally to see dataset coverage and next actions.
| Market | Result | Records | Dataset | Meaning / next action |
|---|---|---|---|---|
| European Union EU | No local match | 0 | Complete annex dataset Regulation (EC) 1223/2009 consolidated to 1 May 2026 | No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review. |
| Great Britain GB | Prohibited | 1Open record 1 | Complete consolidated annex dataset GB retained Regulation 1223/2009 schedules, effective 15 August 2026 | Review every linked record and exact conditions. |
| Canada CA | No local match | 0 | Complete Hotlist snapshot Health Canada Cosmetic Ingredient Hotlist, 13 August 2025 | The Hotlist is an administrative compliance tool, not an exhaustive safety approval list. |
| New Zealand NZ | Prohibited | 1Open record 1 | Complete schedules dataset Cosmetic Products Group Standard schedules effective 1 January 2026 | Review every linked record and exact conditions. |
| ASEAN ASEAN | Prohibited | 1Open record 1 | Complete regional annex dataset ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026 | Review every linked record and exact conditions. |
| China CN | Prohibited | 1Open record 1 | Complete prohibited catalogues plus official-source workflow NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025 | Review every linked record and exact conditions. |
| Japan JP | No local match | 0 | Complete Standards appendices dataset MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot | The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion. |
| South Korea KR | Prohibited | 1Open record 1 | Complete current appendix dataset MFDS Notice 2026-19, effective 18 March 2026 | Review every linked record and exact conditions. |
| United States US | No local match | 0 | Complete enumerated federal ingredient rules eCFR Title 21 issue date 27 August 2026 | FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety. |
| Australia AU | No local match | 0 | Complete cosmetic-relevant Poisons Standard subset plus official workflow Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 | An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction. |
| Brazil BR | Prohibited | 1Open record 1 | Complete prohibited dataset plus current restricted-list workflow ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026 | Review every linked record and exact conditions. |
| India IN | Prohibited | 1Open record 1 | Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4 Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022) | Review every linked record and exact conditions. |
| Saudi Arabia SA | Prohibited | 1Open record 1 | Complete official list index SFDA live prohibited/restricted lists, snapshot 30 August 2026 | Review every linked record and exact conditions. |
Matching market records and conditions
New Zealand
Cosmetic Products Group Standard schedules effective 1 January 2026ASEAN
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026South Korea
MFDS Notice 2026-19, effective 18 March 2026Brazil
ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026India
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)Saudi Arabia
SFDA live prohibited/restricted lists, snapshot 30 August 2026Chemical identity and properties

Tyrothricin
Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis which was previously categorized as Bacillus brevis and Bacillus aneurinolyticus. This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1, TrcB/B1, TrcC/C1, and other more minor contributors) and 40% neutral linear gramicidins (where valine-gramicidin A is often the major gramicidin present, although the mixture composition can vary). Moreover, tyrothricin possesses broad spectrum Gram-positive antibacterial and antifungal activity that has not seen many - if any - significant reportings of microbial resistance during the over 60 years of therapeutic use the complex has provided. Nevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity, although certain formulations that are safe for human use like throat lozenges do exist. — DrugBank
- IUPAC name
- 3-[(3R,6S,9S,12S,15S,17S,20S,22R,25S,28S)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23,26-nonazabicyclo[26.3.0]hentriacontan-17-yl]propanoic acid
- Molecular formula
- C65H85N11O13
- Molecular weight
- 1228.4 g/mol
- Exact mass
- 1227.63283181 Da
- XLogP3
- 1.9
- Topological polar surface area
- 380.0 Ų
- Hydrogen-bond donors
- 12
- Hydrogen-bond acceptors
- 15
- Covalent units
- 1
- Defined stereocentres
- 10
Also known as
16 more reported names
External database identifiers
- ChEMBL:CHEMBL577736
Retrieved from NIH PubChem on 2026-09-02 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Metronidazole
Metronidazole is a member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death. It has a role as a radiosensitizing agent, an antiamoebic agent, an antimicrobial agent, an antiparasitic agent, a xenobiotic, an antibacterial drug, a prodrug, an antitrichomonal drug and an environmental contaminant. It is a primary alcohol, a member of imidazoles and a C-nitro compound. It is a conjugate base of a metronidazole(1+). — ChEBI
- IUPAC name
- 2-(2-methyl-5-nitroimidazol-1-yl)ethanol
- Molecular formula
- C6H9N3O3
- Molecular weight
- 171.15 g/mol
- Exact mass
- 171.06439116 Da
- XLogP3
- 0.0
- Topological polar surface area
- 83.9 Ų
- Hydrogen-bond donors
- 1
- Hydrogen-bond acceptors
- 4
- Covalent units
- 1
- Defined stereocentres
- 0
Also known as
16 more reported names
External database identifiers
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Ethionamide
Ethionamide is a thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide. It has a role as an antitubercular agent, an antilipemic drug, a leprostatic drug, a fatty acid synthesis inhibitor and a prodrug. It is a member of pyridines and a thiocarboxamide. — ChEBI
- IUPAC name
- 2-ethylpyridine-4-carbothioamide
- Molecular formula
- C8H10N2S
- Molecular weight
- 166.25 g/mol
- Exact mass
- 166.05646950 Da
- XLogP3
- 1.1
- Topological polar surface area
- 71.0 Ų
- Hydrogen-bond donors
- 1
- Hydrogen-bond acceptors
- 2
- Covalent units
- 1
- Defined stereocentres
- 0
Also known as
16 more reported names
External database identifiers
- ChEBI:CHEBI:4885
- ChEMBL:CHEMBL1441
- EPA DTXSID:DTXSID0020577
- PubMed:33814510
- PubMed:32808185
- PubMed:26708503
- PubMed:26062974
- PubMed:25051504
- PubMed:23112434
- PubMed:23107633
- PubMed:23106273
- PubMed:23020577
- PubMed:23019444
- PubMed:22952439
- PubMed:22904807
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Methimazole
Methimazole is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen. It has a role as an antithyroid drug. — ChEBI
- IUPAC name
- 3-methyl-1H-imidazole-2-thione
- Molecular formula
- C4H6N2S
- Molecular weight
- 114.17 g/mol
- Exact mass
- 114.02516937 Da
- XLogP3
- -0.3
- Topological polar surface area
- 47.4 Ų
- Hydrogen-bond donors
- 1
- Hydrogen-bond acceptors
- 1
- Covalent units
- 1
- Defined stereocentres
- 0
Also known as
16 more reported names
External database identifiers
- ChEBI:CHEBI:50673
- ChEMBL:CHEMBL1515
- EPA DTXSID:DTXSID4020820
- PubMed:41580965
- PubMed:38685447
- PubMed:34788025
- PubMed:34757178
- PubMed:33814510
- PubMed:32808185
- PubMed:32020584
- PubMed:31697382
- PubMed:31629072
- PubMed:31066087
- PubMed:30814441
- PubMed:30320502
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Ketoconazole
(2S,4R)-ketoconazole is a cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2S,4R)-configuration. It is an enantiomer of a (2R,4S)-ketoconazole. — ChEBI
- IUPAC name
- 1-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone
- Molecular formula
- C26H28Cl2N4O4
- Molecular weight
- 531.4 g/mol
- Exact mass
- 530.1487608 Da
- XLogP3
- 4.3
- Topological polar surface area
- 69.1 Ų
- Hydrogen-bond donors
- 0
- Hydrogen-bond acceptors
- 6
- Covalent units
- 1
- Defined stereocentres
- 2
Also known as
16 more reported names
External database identifiers
- ChEBI:CHEBI:47518
- ChEMBL:CHEMBL295698
- EPA DTXSID:DTXSID60161949
- PubMed:40976440
- PubMed:38795739
- PubMed:38734219
- PubMed:37788138
- PubMed:37077353
- PubMed:36893891
- PubMed:36653537
- PubMed:36621641
- PubMed:36374910
- PubMed:36332690
- PubMed:35478211
- PubMed:35358606
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Nitrofurantoin
Nitrofurantoin is an imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA. It has a role as an antiinfective agent, an antibacterial drug and a hepatotoxic agent. It is an imidazolidine-2,4-dione, an organonitrogen heterocyclic antibiotic, an organooxygen heterocyclic antibiotic and a nitrofuran antibiotic. It is functionally related to a semicarbazide. — ChEBI
- IUPAC name
- 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione
- Molecular formula
- C8H6N4O5
- Molecular weight
- 238.16 g/mol
- Exact mass
- 238.03381930 Da
- XLogP3
- -0.5
- Topological polar surface area
- 121.0 Ų
- Hydrogen-bond donors
- 1
- Hydrogen-bond acceptors
- 6
- Covalent units
- 1
- Defined stereocentres
- 0
Also known as
16 more reported names
External database identifiers
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Furazolidone
Furazolidone is a member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera. It has a role as an antiinfective agent, an antibacterial drug, an EC 1.4.3.4 (monoamine oxidase) inhibitor and an antitrichomonal drug. It is a member of oxazolidines and a nitrofuran antibiotic. — ChEBI
- IUPAC name
- 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
- Molecular formula
- C8H7N3O5
- Molecular weight
- 225.16 g/mol
- Exact mass
- 225.03857033 Da
- XLogP3
- -0.1
- Topological polar surface area
- 101.0 Ų
- Hydrogen-bond donors
- 0
- Hydrogen-bond acceptors
- 6
- Covalent units
- 1
- Defined stereocentres
- 0
Also known as
16 more reported names
External database identifiers
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Dihydrotachysterol
Dihydrotachysterol is a hydroxy seco-steroid that is 9,10-secoergosta-5,7,22-triene substituted by a hydroxy group at position 3. A synthetic analogue of vitamin D that acts a bone density conservation agent. It has a role as a bone density conservation agent. It is a vitamin D, a seco-ergostane and a hydroxy seco-steroid. — ChEBI
- IUPAC name
- trans-(1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
- Molecular formula
- C28H46O
- Molecular weight
- 398.7 g/mol
- Exact mass
- 398.354866087 Da
- XLogP3
- 7.7
- Topological polar surface area
- 20.2 Ų
- Hydrogen-bond donors
- 1
- Hydrogen-bond acceptors
- 1
- Covalent units
- 1
- Defined stereocentres
- 7
Also known as
16 more reported names
External database identifiers
- ChEBI:CHEBI:4591
- ChEMBL:CHEMBL2356023
- EPA DTXSID:DTXSID5022938
- PubMed:15585789
- PubMed:10515239
- PubMed:6262039
- PubMed:4365509
- PubMed:3320562
- PubMed:198519
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

3,4',5-Tribromosalicylanilide
Tribromosalicylanilide is a salicylanilide derivative with bromo- substituents at C-3 and C-5 of the salicylate moiety and at C-4 of the anilide moiety. It is functionally related to a salicylanilide. — ChEBI
- IUPAC name
- 3,5-dibromo-N-(4-bromophenyl)-2-hydroxybenzamide
- Molecular formula
- C13H8Br3NO2
- Molecular weight
- 449.92 g/mol
- Exact mass
- 448.80847 Da
- XLogP3
- 5.0
- Topological polar surface area
- 49.3 Ų
- Hydrogen-bond donors
- 2
- Hydrogen-bond acceptors
- 2
- Covalent units
- 1
- Defined stereocentres
- 0
Also known as
16 more reported names
External database identifiers
- ChEBI:CHEBI:127105
- ChEMBL:CHEMBL24944
- EPA DTXSID:DTXSID4026181
- PubMed:33352258
- PubMed:21826158
- PubMed:20922970
- PubMed:20067776
- PubMed:19668425
- PubMed:18479921
- PubMed:17228788
- PubMed:12755728
Retrieved from NIH PubChem on 2026-09-02 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.
Additional authoritative substance research
Each link searches that source for this identity. A link is a research route, not a claim that the source holds an exact record. What each source is, and its legal weight
Take this record further
Official source and scope
Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.
Open official Decision